Why Did Progressive Stock Go Down?
Shares of insurance giant Progressive (NYSE:PGR) have fallen considerably over…
Sell
27
CC Quote, Financials, Valuation and Earnings
Last price:
$14.45
Seasonality move
:
9.43%
Day range:
$14.22 - $14.72
52-week range:
$13.09 - $29.21
Dividend yield:
6.92%
P/E ratio:
25.80x
P/S ratio:
0.37x
P/B ratio:
3.58x
Volume:
2.9M
Avg. volume:
3.6M
1-year change:
-48.13%
Market cap:
$2.2B
Revenue:
$5.8B
EPS (TTM):
$0.56
Analysts' Opinion
-
Consensus RatingThe Chemours has received a consensus rating of Hold. The company's average rating is a Hold based on 2 Buy ratings, 6 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $22.20, The Chemours has an estimated upside of 53.63% from its current price of $14.45.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $18.00 representing 100% downside risk from its current price of $14.45.
Fair Value
-
According to the consensus of 8 analysts, The Chemours has 53.63% upside to fair value with a price target of $22.20 per share.
CC vs. S&P 500
-
Over the past 5 trading days, The Chemours has underperformed the S&P 500 by -2.61% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
The Chemours does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
The Chemours revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter The Chemours reported revenues of $1.4B.
Earnings Growth
-
The Chemours earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter The Chemours reported earnings per share of -$0.06.
Enterprise value:
5.6B
EV / Invested capital:
1.18x
Price / LTM sales:
0.37x
EV / EBIT:
14.14x
EV / Revenue:
0.96x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-5.59x
Price / Operating cash flow:
432.03x
Enterprise value / EBITDA:
8.00x
Gross Profit (TTM):
$1.2B
Return On Assets:
1.13%
Net Income Margin (TTM):
1.5%
Return On Equity:
12.49%
Return On Invested Capital:
1.84%
Operating Margin:
5.38%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $6.8B | $6.1B | $5.8B | $1.4B | $1.4B | |
| Gross Profit | $1.6B | $1.3B | $1.2B | $255M | $273M | |
| Operating Income | $787M | -$124M | $446M | $2M | $75M | |
| EBITDA | $1.2B | $197M | $694M | $66M | $154M | |
| Diluted EPS | $3.63 | -$1.61 | $0.56 | -$0.13 | -$0.06 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.6B | $3.3B | $3.2B | $3.8B | $3B | |
| Total Assets | $7.1B | $7.6B | $7.6B | $8.3B | $7.5B | |
| Current Liabilities | $1.4B | $1.9B | $1.9B | $2.5B | $1.8B | |
| Total Liabilities | $6.3B | $6.5B | $6.5B | $7.5B | $6.9B | |
| Total Equity | $815M | $1.1B | $1.1B | $739M | $605M | |
| Total Debt | $4B | $3.7B | $3.6B | $4B | $4.1B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $755M | $556M | -$633M | $482M | $138M | |
| Cash From Investing | -$284M | -$229M | -$353M | -$130M | -$107M | |
| Cash From Financing | -$686M | $172M | -$36M | -$5M | $85M | |
| Free Cash Flow | $448M | $186M | -$993M | $347M | $29M | |
CC
Sector
Market Cap
$2.2B
$18.5M
Price % of 52-Week High
49.47%
62.21%
Dividend Yield
6.92%
0%
Shareholder Yield
4.8%
1.29%
1-Year Price Total Return
-48.13%
-11.3%
Beta (5-Year)
1.997
1.012
Dividend yield:
6.92%
Annualized payout:
$1.00
Payout ratio:
170.12%
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$14.41
200-day SMA
Sell
Level
$19.53
Bollinger Bands (100)
Sell
Level
15.88 - 20.32
Chaikin Money Flow
Buy
Level
82.5M
20-day SMA
Sell
Level
$14.56
Relative Strength Index (RSI14)
Sell
Level
42.62
ADX Line
Sell
Level
38.05
Williams %R
Neutral
Level
-28.7958
50-day SMA
Sell
Level
$16.94
MACD (12, 26)
Sell
Level
-0.72
25-day Aroon Oscillator
Sell
Level
-52
On Balance Volume
Sell
Level
-10.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.6757)
Sell
CA Score
(Annual)
Level (-1.8588)
Sell
Beneish M-Score
(Annual)
Level (-1.5804)
Sell
Momentum Score
Level (2)
Buy
Ohlson Score
Level (0.0846)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
The Chemours Co is a provider of chemicals. It delivers customized solutions with a wide range of industrial and specialty chemicals products for various markets including coatings, plastics, refrigeration, air conditioning, etc. The company's operating segments include Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. It generates maximum revenue from the Titanium Technologies segment. The Titanium Technologies segment is a producer of TiO2 pigment, a premium white pigment used to deliver whiteness, brightness, opacity, durability, efficiency, and protection across a variety of applications. Geographically, the company derives a majority of its revenue from North America.
Stock Forecast FAQ
In the current month, CC has received 2 Buy ratings 6 Hold ratings, and 0 Sell ratings. The CC average analyst price target in the past 3 months is $22.20.
-
Where Will The Chemours Stock Be In 1 Year?
According to analysts, the consensus estimate is that The Chemours share price will rise to $22.20 per share over the next 12 months.
-
What Do Analysts Say About The Chemours?
Analysts are divided on their view about The Chemours share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that The Chemours is a Sell and believe this share price will drop from its current level to $18.00.
-
What Is The Chemours's Price Target?
The price target for The Chemours over the next 1-year time period is forecast to be $22.20 according to 8 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 6 analysts rate the stock a Hold.
-
Is CC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for The Chemours is a Hold. 6 of 8 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of CC?
You can purchase shares of The Chemours via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase The Chemours shares.
-
What Is The The Chemours Share Price Today?
The Chemours was last trading at $14.45 per share. This represents the most recent stock quote for The Chemours. Yesterday, The Chemours closed at $14.45 per share.
-
How To Buy The Chemours Stock Online?
In order to purchase The Chemours stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did StoneCo Stock Go Up So Much?
Brazilian fintech company StoneCo (NASDAQ:STNE) has been on a tear…
Is Tenable Stock a Buy, Sell or Hold?
Tenable (NASDAQ:TENB) is a cybersecurity company with a focus on…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3T
P/E Ratio: 41x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Sell
47
RGC alert for Mar 25
Regencell Bioscience Holdings [RGC] is down 18.29% over the past day.
Buy
58
TNXP alert for Mar 25
Tonix Pharmaceuticals Holding [TNXP] is down 2.46% over the past day.
Buy
54
AZEK alert for Mar 25
The AZEK [AZEK] is up 0.12% over the past day.
